公开(公告)号：US11655219B2

公开(公告)日：2023-05-23

申请号：US17103469

申请日：2020-11-24

申请人： LG DISPLAY CO., LTD. ,  Soulbrain Co., Ltd

发明人： Jun-Yun Kim ,  Hyong-Jong Choi ,  Joong-Hwan Yang ,  Bo-Min Seo ,  Tae-Ryang Hong ,  Jin Hee Kim ,  Eun-Chul Shin

IPC分类号： C07D253/08 ,  H01L51/00 ,  H01L51/50 ,  C09K11/06

CPC分类号： C07D253/08 ,  H01L51/0067 ,  H01L51/0071 ,  H01L51/0072 ,  C09K11/06 ,  C09K2211/1007 ,  C09K2211/1014 ,  C09K2211/1018 ,  H01L51/5012

摘要： The present disclosure relates to an organic compound having the following structure of Chemical Formula 1, and an organic light emitting diode (OLED) and an organic light emitting device including the organic compound. The organic compound includes a triazine moiety of an electron acceptor and a fused hetero aromatic moiety of an electron donor separated from the triazine moiety. The organic compound includes the electron acceptor moiety and the electron donor moiety in a single molecule, thus charges can be moved in the molecule. Also, since the organic compound includes the rigid fused hetero aromatic ring, three dimensional conformation of the organic compound is limited, and therefore the compound may have excellent luminous efficiency and color purity.

公开(公告)号：US20170360784A1

公开(公告)日：2017-12-21

申请号：US15639575

申请日：2017-06-30

申请人： University of Utah Research Foundation

发明人： Vincente Planelles ,  Alberto Bosque-Pardos ,  Chris M. Ireland ,  Ryan Van Wagoner ,  Mary Kay Harper-Ireland ,  John Alan Maschek

IPC分类号： A61K31/501 ,  C07D403/04 ,  C07D253/08 ,  C07D249/18 ,  C07D231/54 ,  A61K31/416 ,  A61K45/06 ,  A61K31/53 ,  A61K31/437 ,  A61K31/4192 ,  C07D471/04 ,  C07D249/04

CPC分类号： A61K31/501 ,  A61K31/416 ,  A61K31/4192 ,  A61K31/437 ,  A61K31/53 ,  A61K45/06 ,  C07D231/54 ,  C07D249/04 ,  C07D249/18 ,  C07D253/08 ,  C07D403/04 ,  C07D471/04 ,  A61K2300/00

摘要： In one aspect, the invention relates to triazol-1-ol compounds, analogs thereof, compositions comprising same, and methods of using same, alone or in combination with other agents, to reactivate latent retroviruses, and more particularly to reactivate latent HIV-1. Such compounds, compositions, and methods can be used, for example, in connection with diagnosing and/or treating a retrovirus, and more specifically HIV-1. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

公开(公告)号：US20170355664A1

公开(公告)日：2017-12-14

申请号：US15581327

申请日：2017-04-28

申请人： THERAVANCE BIOPHARMA R&D IP, LLC

发明人： Melissa Fleury ,  Adam D. Hughes

IPC分类号： C07C229/22 ,  A61K31/4439 ,  C07D401/04 ,  C07D405/14 ,  C07C271/22 ,  C07D249/12 ,  C07D231/20 ,  C07D261/18 ,  A61K31/4192 ,  A61K31/415 ,  C07D257/04 ,  A61K31/42 ,  C07D207/26 ,  A61K31/675 ,  A61K31/41 ,  A61K31/4155 ,  A61K45/06 ,  C07D249/18 ,  C07F9/6503 ,  C07D249/04 ,  C07D263/38 ,  A61K31/4196 ,  C07D253/08 ,  C07D231/18 ,  C07D405/12 ,  C07D231/14

CPC分类号： C07C229/22 ,  A61K31/41 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/4192 ,  A61K31/4196 ,  A61K31/42 ,  A61K31/4439 ,  A61K31/675 ,  A61K45/06 ,  C07C271/22 ,  C07D207/26 ,  C07D231/14 ,  C07D231/18 ,  C07D231/20 ,  C07D249/04 ,  C07D249/12 ,  C07D249/18 ,  C07D253/08 ,  C07D257/04 ,  C07D261/18 ,  C07D263/38 ,  C07D401/04 ,  C07D405/12 ,  C07D405/14 ,  C07F9/65031

摘要： In one aspect, the invention relates to compounds having the formula XII: where Ra, Rb, R2, R7, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds described herein are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.

公开(公告)号：US09670140B2

公开(公告)日：2017-06-06

申请号：US14792810

申请日：2015-07-07

申请人： Adam D. Hughes

发明人： Adam D. Hughes

IPC分类号： C07C229/22 ,  C07C271/22 ,  C07D249/18 ,  A61K31/4192 ,  A61K45/06 ,  C07D231/20 ,  A61K31/415 ,  C07D405/12 ,  A61K31/4155 ,  A61K31/4439 ,  C07D401/04 ,  C07D405/14 ,  C07D231/14 ,  C07D261/18 ,  A61K31/42 ,  C07D249/04 ,  C07D249/12 ,  A61K31/4196 ,  C07D257/04 ,  A61K31/41 ,  A61K31/675 ,  C07F9/6503 ,  C07D231/18 ,  C07D253/08 ,  C07D207/26 ,  C07D263/38

CPC分类号： C07C229/22 ,  A61K31/41 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/4192 ,  A61K31/4196 ,  A61K31/42 ,  A61K31/4439 ,  A61K31/675 ,  A61K45/06 ,  C07C271/22 ,  C07D207/26 ,  C07D231/14 ,  C07D231/18 ,  C07D231/20 ,  C07D249/04 ,  C07D249/12 ,  C07D249/18 ,  C07D253/08 ,  C07D257/04 ,  C07D261/18 ,  C07D263/38 ,  C07D401/04 ,  C07D405/12 ,  C07D405/14 ,  C07F9/65031

摘要： In one aspect, the invention relates to compounds having the formula XII: where Ra, Rb, R2, R7, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds described herein are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.

公开(公告)号：US20170095480A1

公开(公告)日：2017-04-06

申请号：US15382490

申请日：2016-12-16

申请人： Takeda Pharmaceutical Company Limited

发明人： Stephen Hitchcock ,  Betty Lam ,  Holger Monenschein ,  Holly Reichard

IPC分类号： A61K31/53

CPC分类号： A61K31/53 ,  C07D253/08

摘要： The present invention provides a method for treating a disease, disorder or condition associated with GPR139 using compounds of formula 1: which are agonists of GPR139, certain compounds encompassed by formula 1, pharmaceutical compositions thereof, processes for making the compounds, and intermediates thereof.

公开(公告)号：US20170022171A1

公开(公告)日：2017-01-26

申请号：US15301392

申请日：2015-03-31

申请人： Bayer Pharma Aktiengesellschaft

发明人： Hartmut BECK ,  Volkhart Min-Jian LI ,  Yolanda CANCHO GRANDE ,  Andreas TIMMERMANN ,  Dirk BROHM ,  Hannah JÖRISSEN ,  Pamela BOGNER ,  Michael GERISCH ,  Dieter LANG

IPC分类号： C07D253/08 ,  A61K31/53 ,  C07D413/12 ,  A61K45/06

CPC分类号： C07D253/08 ,  A61K31/53 ,  A61K45/06 ,  C07D413/12

摘要： The present application relates to novel 2,5-disubstituted cyclopentanecarboxylic acid derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of respiratory, pulmonary and cardiovascular disorders.

摘要翻译： 本申请涉及新的2,5-二取代的环戊烷羧酸衍生物，其制备方法，单独使用或组合用于治疗和/或预防疾病及其用于生产用于治疗和/ 或预防疾病，特别是用于治疗和/或预防呼吸，肺和心血管疾病。

公开(公告)号：US20160340323A1

公开(公告)日：2016-11-24

申请号：US15227638

申请日：2016-08-03

申请人： Merck Patent GmbH

发明人： Bayard R. HUCK ,  Ruoxi LAN ,  Justin POTNICK ,  Lizbeth Celeste DESELM ,  Mark W. CRONIN, JR. ,  Constantin NEAGU ,  Xiaoling CHEN ,  Roch BOIVIN ,  Theresa L. JOHNSON ,  Andreas GOUTOPOULOS

IPC分类号： C07D253/08 ,  C07D403/12 ,  C07D401/12

CPC分类号： C07D253/08 ,  A61K31/519 ,  A61K31/53 ,  A61K45/06 ,  C07D401/12 ,  C07D403/12 ,  C07D471/04

摘要： Novel azaquinazoline carboxamide derivatives of formula (I) wherein W1, W2, W3, W4, R1, R2, R3 and m which are defined above, are p70S6K inhibitor, and can be employed, inter alia, for the treatment of hyperproliferative disorders.

摘要翻译： 其中上述定义的W1，W2，W3，W4，R1，R2，R3和m是p70S6K抑制剂，并且可以用于治疗过度增殖性疾病。

公开(公告)号：US20160250233A1

公开(公告)日：2016-09-01

申请号：US15148241

申请日：2016-05-06

申请人： Siga Technologies, Inc.

发明人： Chelsea OLSEN ,  Robert JORDAN ,  Dongcheng DAI ,  Tove BOLKEN ,  Dennis E. HRUBY

IPC分类号： A61K31/635 ,  A61K31/18 ,  A61K31/53 ,  A61K31/517 ,  A61K31/63 ,  A61K9/00

CPC分类号： A61K31/635 ,  A61K9/0019 ,  A61K31/18 ,  A61K31/473 ,  A61K31/502 ,  A61K31/517 ,  A61K31/519 ,  A61K31/522 ,  A61K31/53 ,  A61K31/63 ,  C07C311/46 ,  C07D221/14 ,  C07D237/32 ,  C07D239/88 ,  C07D239/96 ,  C07D241/44 ,  C07D253/08 ,  C07D401/12 ,  C07D403/06 ,  C07D405/12 ,  C07D409/12 ,  C07D417/12 ,  C07D473/08 ,  C07D491/048 ,  C07D495/04 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/389 ,  Y02A50/393 ,  Y02A50/395

摘要： Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by flavivirus is disclosed, i.e., including but not limited to, Dengue virus, West Nile virus, yellow fever virus, Japanese encephalitis virus, and tick-borne encephalitis virus.

摘要翻译： 公开了通过施用治疗有效量的某些化合物来治疗病毒感染的化合物，方法和药物组合物。 还公开了制备化合物的方法和使用该化合物的方法及其药物组合物。 特别地，公开了由黄病毒引起的病毒感染的治疗和预防，即包括但不限于登革病毒，西尼罗河病毒，黄热病病毒，日本脑炎病毒和蜱传脑炎病毒。

公开(公告)号：US08569304B2

公开(公告)日：2013-10-29

申请号：US12398920

申请日：2009-03-05

申请人： Subhakar Dey ,  Darryl J. C. Pappin ,  Subhasish Purkayastha ,  Sasi Pillai ,  James M. Coull

发明人： Subhakar Dey ,  Darryl J. C. Pappin ,  Subhasish Purkayastha ,  Sasi Pillai ,  James M. Coull

IPC分类号： A61K31/497 ,  C07D241/04 ,  C07D295/00 ,  C07D403/00

CPC分类号： C07D207/46 ,  C07D241/08 ,  C07D253/08 ,  C07D295/03 ,  C07D295/15

摘要： In some embodiments, this invention pertains to active esters of N-substituted piperazine acetic acid, including isotopically enriched versions thereof. In some embodiments, this invention pertains to methods for the preparation of active esters of N-substituted piperazine acetic acid, including isotopically enriched versions thereof.

摘要翻译： 在一些实施方案中，本发明涉及N-取代的哌嗪乙酸的活性酯，包括同位素富集的形式。 在一些实施方案中，本发明涉及制备N-取代的哌嗪乙酸的活性酯的方法，包括同位素富集的形式。

公开(公告)号：US07932388B2

公开(公告)日：2011-04-26

申请号：US12001734

申请日：2007-12-11

申请人： Darryl J. C. Pappin ,  Sasi Pillai ,  James M. Coull

发明人： Darryl J. C. Pappin ,  Sasi Pillai ,  James M. Coull

IPC分类号： C07D241/04 ,  C07D295/067

CPC分类号： C07D207/46 ,  C07D241/08 ,  C07D253/08 ,  C07D295/03 ,  C07D295/15

摘要： In some embodiments, this invention pertains to isotopically enriched N-substituted piperazines. In some embodiments, this invention pertains to methods for the preparation of isotopically enriched N-substituted piperazines.

摘要翻译： 在一些实施方案中，本发明涉及同位素富集的N-取代的哌嗪。 在一些实施方案中，本发明涉及制备同位素富集的N-取代哌嗪的方法。